Writing for Bloomberg BNA, Robyn Maguire Analyzes How the FDA’s 3D Printing Guidance Informs Product LiabilityPrint PDF
Robyn Maguire, a partner in Nutter’s Litigation Department and Product Liability practice group, contributed an article to Bloomberg BNA that explored the FDA’s recent 3D printing guidance. In the article, “How the FDA’s New 3D Printing Guidance Informs Product Liability,” Robyn explains that given the dearth of case law in the additive manufacturing (AM) process, it’s still unclear how traditional product liability principles will be applied to medical device design and manufacturing. Given the speed of innovation in the 3D printing industry, she expects that the FDA will release additional information and guidance concerning the role of nontraditional manufacturing facilities as well as bio-printing of biological materials
This article also appeared in Bloomberg Law's Big Law Business.